Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAHtalyst: Crinecerfont in Adult Subjects With Classic Congenital Adrenal Hyperplasia
NCT04490915Phase 3Active, not recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Dec 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of crinecerfont in congenital adrenal hyperplasia (CAH), sponsored by Neurocrine Biosciences. Started Dec 2020; status: active, not recruiting.
02
Drugs
crinecerfont
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT04490915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04490915.